Trials / Active Not Recruiting
Active Not RecruitingNCT06008353
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The central objective of this study is to characterize the demographic of an ES-SCLC Brazilian cohort treated with durvalumab. Secondarily, to assess the outcomes of durvalumab-based regimens in 1L treatment of ES-SCLC Brazilian patients from the private health care setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational study | This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care. |
Timeline
- Start date
- 2024-01-18
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
- First posted
- 2023-08-23
- Last updated
- 2024-12-19
Locations
5 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT06008353. Inclusion in this directory is not an endorsement.